Biophytis SA (FR:ALBPS) has released an update.
Biophytis SA, a clinical-stage biotechnology company, has announced its upcoming Combined General Meeting scheduled for June 24, 2024, to be held at Sorbonne Université in Paris. Shareholders are encouraged to vote in advance via mail, proxy, or the online platform VOTACCESS. The company focuses on developing therapies for age-related diseases and has a lead drug candidate, BIO101, in various stages of clinical development.
For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.